Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women

Henry, Dan; Bettis, Robert; Riffer, Ernie; Haverstock, Daniel; Kowalsky, Steven F.; Manning, Kathryn; Hamed, Kamal; Church, D.

doi:10.1016/s0149-2918(02)80099-6

Cited by 54 publications

(53 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these studies, a total of only 14 patients were infected with such organisms. 8,23 There was a similar lack of data for fluoroquinolones 24,25 but relatively more data for TMP-SMX. 8,40,41 More research is needed to better determine the probability of curing UTIs when the causative organism is resistant to the antibiotic used, especially given how increasingly common this scenario is in primary care.…”

Section: Discussionmentioning

confidence: 99%

“…For simplicity, the Figure does not include the probability of vaginal yeast infection, which was calculated for each outcome on the basis of published probabilities. 7,[22][23][24][25] Other potential antibiotic effects or complications (eg, StevensJohnson syndrome) were considered rare and not included in our model, given that a previous investigation of uncomplicated UTIs found that expensive but uncommon events had almost no effect on overall treatment costs. 26 Finally, a model was constructed that compared all 3 treatments: nitrofurantoin, TMP-SMX, and fluoroquinolones.…”

Section: Methodsmentioning

confidence: 99%

“…Probabilities for clinical events were obtained from published estimates, [3][4][5]7,8,[23][24][25]31,37,[40][41][42][43][44][45][46][47][48][49] with use of the mean value as the point estimate in the model (Table 2). These estimates were derived from previous models and the systematic review of the literature.…”

Section: Probabilitiesmentioning

confidence: 99%

See 2 more Smart Citations

Nitrofurantoin Compares Favorably to Recommended Agents as Empirical Treatment of Uncomplicated Urinary Tract Infections in a Decision and Cost Analysis

McKinnell

Stollenwerk

Jung

et al. 2011

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective: To analyze the costs of nitrofurantoin use compared to those of other antibiotics recommended for treatment of uncomplicated urinary tract infection (UTI). Patients and MethOds:We used a decision analysis model to perform cost-minimization and sensitivity analyses to determine the level of trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolone resistance that would favor the use of nitrofurantoin as a first-line empirical treatment of uncomplicated UTIs. The model used a program perspective to evaluate costs.Results: Nitrofurantoin was cost-minimizing when the prevalence of fluoroquinolone resistance exceeded 12% among uropathogens or the prevalence of TMP-SMX resistance exceeded 17%. On 2-way sensitivity analysis, variables that had a significant impact on our cost-minimization threshold included cost of antibiotics and probability of clinical cure with antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Nitrofurantoin Compares Favorably to Recommended Agents as Empirical Treatment of Uncomplicated Urinary Tract Infections in a Decision and Cost Analysis

McKinnell

Stollenwerk

Jung

et al. 2011

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…Araştırmamızda FT ile karşılaştırdığımız CP ile ilgili yapılan araştırmalarda günde iki kez 250 mg CP ve gün-de tek doz 500 mg CP nin benzer kür oranlarına sahip olduğu bulunmuştur. [15,16] Bununla beraber azalan tedavi süresi-nin yan etki insidansını günde iki doz CP ile günde tek doz 3 g FT karşılaştırıldı. Benzer klinik ve mikrobiyolojik kür oran-ları elde edildi.…”

Section: Discussionunclassified

Comparison of Fosfomysin Trometamol and Ciprofloxacin in Uncomplicated Urinary Tract Infections

et al. 2011

View full text Add to dashboard Cite

SUMMARY Objectives Acute urinary tract infection (UTI) is one of the most common infections requiring empirical antibiotic therapy. Selection of efficient and safe antimicrobial agent is important in the emergency department (ED). The aim of this study is to compare the microbiological and clinical efficiency of single-dose fosfomycin trometamol (FT) therapy with a 3-day course of ciprofloxacin (CP) for the treatment of uncomplicated UTI. Methods ÖZET AmaçAkut komplike olmayan alt üriner sistem enfeksiyonları en sık ampirik antibiyotik reçete edilen enfeksiyonlardır. Acil serviste (AS) gü-venilir ve etkin bir antimikrobiyal ajan seçimi önemlidir. Bu çalış-manın amacı, acil servise başvuran akut komplike olmayan üriner sistem enfeksiyonu olan hastalarda tek doz fosfomisin trometorol (FT) ve 3 gün siprofloksasinin (CP) klinik ve mikribiyolojik etkinliği-nin karşılaştırılmasıdır. Gereç ve YöntemBu randomize, tek kör, prospektif çalışmada AS'ye semptomları son 72 saat içinde başlayan, dizüri, idrara sıkışma hissi ve sık idrara gitme şikayeti ile başvuran 18-65 yaş kadın hastalar değerlen-dirildi. Bir grup hasta tek doz FT, diğer grup 3 günlük CP tedavisi aldı. İlk idrar kültürlerinde üreme olan hastalar çalışma grubunu oluşturdu. Tedaviden sonraki 7.-10. günlerde klinik ve mikrobiyolojik kür değerlendirildi. Tedavi rejimlerinin etkinliği ki-kare testi ile karşılaştırıldı. BulgularÇalışmadaki 81 kadının yaş ortalaması 30±2 idi. FT grubunda 40, CP grubunda 41 hasta vardı. En sık izole edilen üropatojen 50 ör-nekte bulunan E. coli idi (%61.3). Klinik olarak iyileşme CP grubunda 38 (%93), FT grubunda 38 (%96) hastada saptandı (χ²: 0,347, df: 1, p=0.275). Bakteriyolojik eradikasyon CP grubundaki hastaların 27 (%65,8), FT grubundaki hastaların 32'sinde (%80) elde edildi (χ²: 0.1591, df: 1, p=0.207). FT grubunda yalnızca 3 hastada (%7.5) pirozis görülürken CP grubunda 4 hastada (%10) pirozis, 5 hastada (%12) bulantı görüldü. SonuçKomplike olmayan üriner sistem enfeksiyonu olan kadın hastalarda tek doz FT ampirik antibiyotik olarak CP kadar etkin ve güvenlidir.Anahtar sözcükler: Ampirik tedavi; fosfomisin trometamol; idrar yolu infeksiyonu; siprofloksasin. 104

show abstract

“…Nitrofurantoin is not associated with plasmid-mediated resistance and is a suitable choice for patients with recent exposure to other antimicrobial agents (Fihn 2003). Fluoroquinolones offer excellent activity and are usually well tolerated (Henry et al 2002). Their resistance is less than 5% in most regions (Hooton et al 2004, Warren et al 1999); however resistance rates are beginning to increase worldwide (although not as high as that of TMP-SMX) (Yamamoto et al 2010) (Muratani and Matsumoto 2006).…”

Section: Managementmentioning

confidence: 99%

Current Management Strategies for Uncomplicated and Complicated Cystitis

Davis¹,

Flood²

2011

Urinary Tract Infections

View full text Add to dashboard Cite

Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women

Cited by 54 publications

References 23 publications

Nitrofurantoin Compares Favorably to Recommended Agents as Empirical Treatment of Uncomplicated Urinary Tract Infections in a Decision and Cost Analysis

Nitrofurantoin Compares Favorably to Recommended Agents as Empirical Treatment of Uncomplicated Urinary Tract Infections in a Decision and Cost Analysis

Comparison of Fosfomysin Trometamol and Ciprofloxacin in Uncomplicated Urinary Tract Infections

Current Management Strategies for Uncomplicated and Complicated Cystitis

Contact Info

Product

Resources

About